Natixis Advisors LLC Acquires New Shares in Enovis Co. (NYSE:ENOV)

Natixis Advisors LLC purchased a new position in Enovis Co. (NYSE:ENOV) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 12,680 shares of the company’s stock, valued at approximately $546,000.

Several other large investors have also made changes to their positions in the business. Price T Rowe Associates Inc. MD grew its stake in shares of Enovis by 88.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 381,118 shares of the company’s stock valued at $23,802,000 after purchasing an additional 179,276 shares during the period. Janus Henderson Group PLC lifted its stake in shares of Enovis by 100.6% in the 1st quarter. Janus Henderson Group PLC now owns 378,020 shares of the company’s stock valued at $23,606,000 after purchasing an additional 189,584 shares during the period. First Eagle Investment Management LLC increased its position in shares of Enovis by 13.3% in the 2nd quarter. First Eagle Investment Management LLC now owns 284,596 shares of the company’s stock valued at $12,864,000 after buying an additional 33,300 shares in the last quarter. Sei Investments Co. increased its position in shares of Enovis by 50.9% in the 2nd quarter. Sei Investments Co. now owns 223,358 shares of the company’s stock valued at $10,096,000 after buying an additional 75,317 shares in the last quarter. Finally, King Luther Capital Management Corp increased its holdings in Enovis by 45.2% during the 2nd quarter. King Luther Capital Management Corp now owns 177,862 shares of the company’s stock worth $8,039,000 after purchasing an additional 55,385 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Wall Street Analyst Weigh In

ENOV has been the subject of several analyst reports. Needham & Company LLC restated a “buy” rating and issued a $65.00 price objective on shares of Enovis in a report on Thursday, November 7th. JMP Securities initiated coverage on shares of Enovis in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $62.00 price objective on the stock. JPMorgan Chase & Co. decreased their target price on shares of Enovis from $53.00 to $50.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Finally, Evercore ISI decreased their target price on shares of Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 1st. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $67.00.

Enovis Price Performance

Shares of NYSE ENOV opened at $48.45 on Friday. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The firm’s 50-day moving average price is $43.01 and its 200-day moving average price is $44.90. The firm has a market capitalization of $2.71 billion, a P/E ratio of -22.12 and a beta of 1.91. Enovis Co. has a 1-year low of $38.27 and a 1-year high of $65.03.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.11. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The business had revenue of $505.22 million during the quarter, compared to the consensus estimate of $504.44 million. During the same period in the prior year, the firm posted $0.56 EPS. The firm’s quarterly revenue was up 21.0% compared to the same quarter last year. Equities research analysts anticipate that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.